

Special Issue

Impacts of the Kallikrein–Kinin System in Cancer and Its Treatment: A Focus on Drug Delivery and Formulations

Message from the Guest Editors

This Special Issue aims to collate articles that address the role of the kallikrein–kinin system in cancer pathophysiology and the adverse effects of anticancer therapy. We particularly welcome submissions that explore the potential of novel drug delivery approaches and formulations targeting the kallikrein–kinin system, as well as their preclinical and clinical applications in cancer treatment.

In this Special Issue, original research articles and reviews are welcome to be submitted. Research areas may include, but are not limited to, the following:

- Kallikrein–kinin system in cancer pathophysiology;
- Kallikrein–kinin system in cancer pain;
- Kallikrein–kinin system in the adverse effects of anticancer therapy;
- Kallikrein–kinin systems in anticancer therapy-associated pain;
- Kallikrein–kinin system-targeted drug delivery systems;
- Kallikrein–kinin system-targeted formulations;
- Nanoparticle-based delivery systems for kallikrein–kinin system modulators;
- Liposomal formulations targeting the kallikrein–kinin system;
- Polymeric micelles for kallikrein–kinin system-targeted drug delivery;
- Prodrug strategies for kallikrein–kinin system modulation.

Guest Editors

Dr. Indiara Brusco

1. Graduate Program in Biological Sciences: Toxicological Biochemistry, Center of Natural and Exact Sciences, Federal University of Santa Maria, Camobi, Santa Maria 97105-900, RS, Brazil

2. Graduate Program in Environmental Sciences, Community University of Chapecó Region, Efapi, Chapecó 89809-000, SC, Brazil

Dr. Sara Marchesan De Oliveira

Graduate Program in Biological Sciences: Toxicological Biochemistry, Center of Natural and Exact Sciences, Federal University of Santa Maria, Camobi, Santa Maria 97105-900, RS, Brazil



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/234556

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).